66 related articles for article (PubMed ID: 38541113)
1. Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis.
Mümmler C; Mertsch P; Barnikel M; Haubner F; Schönermarck U; Grabmaier U; Schulze-Koops H; Behr J; Kneidinger N; Milger K
J Asthma Allergy; 2024; 17():557-572. PubMed ID: 38860030
[TBL] [Abstract][Full Text] [Related]
2. Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis.
Pelaia C; Crimi C; Benfante A; Caiaffa MF; Campisi R; Candia C; Carpagnano GE; Carrieri I; D'Amato M; Detoraki A; Barbaro MPF; Lombardo N; Macchia L; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Ricciardi L; Scichilone N; Scioscia G; Spadaro G; Tondo P; Uletta Lionetti S; Valenti G; Vatrella A; Crimi N; Pelaia G
Respirology; 2024 Jun; ():. PubMed ID: 38847185
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Early and Late Lung Function Improvement in Severe Eosinophilic Asthma on Type2-Biologics in the PRISM Study.
Pham DD; Lee JH; Kwon HS; Song WJ; Cho YS; Kim H; Kwon JW; Park SY; Kim S; Hur GY; Kim BK; Nam YH; Yang MS; Kim MY; Kim SH; Lee BJ; Lee T; Park SY; Kim MH; Cho YJ; Park C; Jung JW; Park HK; Kim JH; Moon JY; Bhavsar P; Adcock I; Chung KF; Kim TB
Lung; 2024 Feb; 202(1):41-51. PubMed ID: 38252134
[TBL] [Abstract][Full Text] [Related]
4. Anti-IL-4R versus Anti-IL-5/5R after Anti-IL-5/5R failure in asthma: an emulated target trial.
Valery S; Simon-Tillaux N; Devouassoux G; Bonniaud P; Beurnier A; Boudjemaa A; Chenivesse C; Bourdin A; Gauquelin L; Guillo S; Taillé C; Estellat C;
J Allergy Clin Immunol; 2024 Jun; ():. PubMed ID: 38848878
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Effectiveness of Anti-IL-4R Therapy Following Suboptimal Response to Anti-IL-5/5R Therapy in Severe Eosinophilic Asthma.
Gates J; Hearn A; Mason T; Fernandes M; Green L; Thomson L; Roxas C; Lam J; d'Ancona G; Nanzer AM; Dhariwal J; Jackson DJ
J Allergy Clin Immunol Pract; 2024 Apr; ():. PubMed ID: 38583517
[TBL] [Abstract][Full Text] [Related]
6. Asthma Remission one, none and one-hundred thousand: the relevance of the patient's view.
Bonini M; Barbaglia S; Camiciottoli G; Del Giacco S; Di Marco F; Matucci A; Micheletto C; Papi A; Pasqualetti P; Pelaia G; Ricciardolo FLM; Rogliani P; Senna G; Triggiani M; Vancheri C; Canonica GW
J Asthma; 2024 Jun; ():1-25. PubMed ID: 38870405
[TBL] [Abstract][Full Text] [Related]
7. Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy.
Oprescu B; Raduna O; Mihaicuta S; Frent S
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541113
[No Abstract] [Full Text] [Related]
8. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
12. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
Menzies-Gow A; Hoyte FL; Price DB; Cohen D; Barker P; Kreindler J; Jison M; Brooks CL; Papeleu P; Katial R
Adv Ther; 2022 May; 39(5):2065-2084. PubMed ID: 35287231
[TBL] [Abstract][Full Text] [Related]
13. Phenotype overlap in the natural history of asthma.
Ricciardolo FLM; Guida G; Bertolini F; Di Stefano A; Carriero V
Eur Respir Rev; 2023 Jun; 32(168):. PubMed ID: 37197769
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
